## Merrie Mosedale

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8123503/publications.pdf

Version: 2024-02-01

516561 501076 2,629 29 16 28 citations g-index h-index papers 30 30 30 4918 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Mitochondrial Overload and Incomplete Fatty Acid Oxidation Contribute to Skeletal Muscle Insulin Resistance. Cell Metabolism, 2008, 7, 45-56.	7.2	1,618
2	Drugâ€induced liver injury: Advances in mechanistic understanding that will inform risk management. Clinical Pharmacology and Therapeutics, 2017, 101, 469-480.	2.3	155
3	PPARÎ <sup>3</sup> coactivator-1α contributes to exercise-induced regulation of intramuscular lipid droplet programming in mice and humans. Journal of Lipid Research, 2013, 54, 522-534.	2.0	89
4	Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. Food and Chemical Toxicology, 2015, 76, 19-26.	1.8	80
5	Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury?. Toxicological Sciences, 2016, 151, 365-375.	1.4	71
6	Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicological Sciences, 2017, 155, 61-74.	1.4	71
7	Expression of Neurexin, Neuroligin, and Their Cytoplasmic Binding Partners in the Pancreatic β-Cells and the Involvement of Neuroligin in Insulin Secretion. Endocrinology, 2008, 149, 6006-6017.	1.4	64
8	Bioprinted liver provides early insight into the role of Kupffer cells in TGF- $\hat{l}^21$ and methotrexate-induced fibrogenesis. PLoS ONE, 2019, 14, e0208958.	1.1	59
9	Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach. Toxicological Sciences, 2017, 156, kfw269.	1.4	46
10	A Systems Biology Approach Utilizing a Mouse Diversity Panel Identifies Genetic Differences Influencing Isoniazid-Induced Microvesicular Steatosis. Toxicological Sciences, 2014, 140, 481-492.	1.4	44
11	miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model. Toxicological Sciences, 2018, 161, 149-158.	1.4	40
12	Quantitative Systems Toxicology Analysis of <i>In Vitro </i> Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury. Toxicological Sciences, 2019, 167, 458-467.	1.4	35
13	Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. Journal of Medicinal Chemistry, 2020, 63, 6436-6461.	2.9	34
14	Neurexin-1α Contributes to Insulin-containing Secretory Granule Docking. Journal of Biological Chemistry, 2012, 287, 6350-6361.	1.6	32
15	Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences, 2019, 170, 499-508.	1.4	30
16	Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials. Clinical Pharmacology and Therapeutics, 2017, 102, 961-969.	2.3	29
17	Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach. Toxicological Sciences, 2019, 172, 265-278.	1.4	22
18	Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa). Toxicological Sciences, 2018, 161, 401-411.	1.4	17

#	Article	IF	CITATIONS
19	Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug. Toxicology and Applied Pharmacology, 2014, 280, 21-29.	1.3	14
20	Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression. Journal of Pharmaceutical Sciences, 2021, 110, 412-421.	1.6	14
21	Optimized Methods to Explore the Mechanistic and Biomarker Potential of Hepatocyte-Derived Exosomes in Drug-Induced Liver Injury. Toxicological Sciences, 2018, 163, 92-100.	1.4	13
22	Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury. Chemical Research in Toxicology, 2020, 33, 2745-2748.	1.7	13
23	Human-relevant mechanisms and risk factors for TAK-875-Induced liver injury identified via a gene pathway-based approach in Collaborative Cross mice. Toxicology, 2021, 461, 152902.	2.0	12
24	Differential Detergent Fractionation of Membrane Protein From Small Samples of Hepatocytes and Liver Tissue for Quantitative Proteomic Analysis of Drug Metabolizing Enzymes and Transporters. Journal of Pharmaceutical Sciences, 2021, 110, 87-96.	1.6	8
25	Mouse Population-Based Approaches to Investigate Adverse Drug Reactions. Drug Metabolism and Disposition, 2018, 46, 1787-1795.	1.7	7
26	Characterization of primary mouse hepatocyte spheroids as a model system to support investigations of drug-induced liver injury. Toxicology in Vitro, 2021, 70, 105010.	1.1	6
27	Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine. American Journal of Pharmaceutical Education, 2018, 82, 6652.	0.7	4
28	Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. Toxicological Sciences, 2021, 179, 95-107.	1.4	2
29	Fit-For-Purpose Hepatocyte Models Enable the Identification of Early Events Contributing to Idelalisib-Induced Liver Injury. Applied in Vitro Toxicology, 2020, 6, 110-119.	0.6	O